Abiomed, Inc.
ABMD · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.76 | 5.62 | -1.46 | 0.38 |
| FCF Yield | 1.66% | 1.54% | 4.13% | 1.67% |
| EV / EBITDA | 37.23 | 57.32 | 24.72 | 53.53 |
| Quality | ||||
| ROIC | 17.39% | 12.55% | 16.99% | 23.02% |
| Gross Margin | 81.76% | 80.90% | 82.01% | 83.16% |
| Cash Conversion Ratio | 2.09 | 1.22 | 1.55 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.06% | 3.27% | 12.30% | 20.00% |
| Free Cash Flow Growth | 12.85% | -18.35% | 30.13% | 52.32% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.94 | -0.75 | -0.52 |
| Interest Coverage | 7.48 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.00 | 2.00 | 1.68 | 1.60 |
| Cash Conversion Cycle | 145.80 | 146.04 | 175.01 | 180.43 |